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The Great Pandemic of 2020 shows how much public health around the world depends 
on effective global and domestic governance. Yet for too long, global health governance 
and domestic regulatory governance have remained largely separate fields of 
scholarship and practice. In her book, Global Health Justice and Governance, Jennifer 
Prah Ruger offers scholars and practitioners of regulatory governance an excellent 
opportunity to see how domestic regulation shares many of the same problems, 
strategies, and challenges as global health governance. These commonalities reinforce 
how much national and subnational regulators can learn from global health 
governance. Drawing on insights from Prah Ruger’s impressive book, I offer seven 
lessons for domestic regulators around the world to use to improve their performance, 
arguing that it is vital for regulators to see themselves as operating in a larger social 
environment in which they must remain agile, vigilant, and responsive to other actors 




Scientists and scholars will be studying for decades the causes and implications of the 
COVID-19 pandemic that overwhelmed the world in 2020. For now, as the pandemic 
continues to rage and fatalities mount in the millions worldwide, the final extent of 
mortality and morbidity effects from the viral outbreak cannot be known, nor can we yet 
gauge the full losses from the resulting global economic dislocation. But even from the 
earliest days of the rampage caused by the SARS-CoV-2 virus, it has been evident how 
much public health effectiveness around the world depends not only on the quality of 
global health governance but also on the performance of domestic regulatory institutions.  
The fact that the earliest cases of SARS-CoV-2 infection appeared among workers 
at the Huanan Seafood Wholesale Market in Wuhan, China1 has brought renewed 
attention to the ways that viral transmission can occur when people and animals, 
domestic and wild, all closely comingle in certain food markets, particularly those in 
Asia.2 Even if SARS-CoV-2 did not actually originate at the food market itself, its early 
identification there serves as a reminder of how improved local sanitation and food 
regulations, including those controlling trade in wild and exotic animals, can help prevent 
or slow the spread of pathogenic outbreaks.3 
Another principal way that domestic regulation clearly affects global health stems 
from how nations are able to respond in the face of a virulent pathogen’s transnational 
spread. Once the transmission of SARS-CoV-2 crossed national borders, actions by 
domestic regulators proved pivotal to the virus’s ability to gain a foothold and spread 
further. Although both South Korea and the United States announced their first cases of 
the novel coronavirus on the same day in January 2020, the contrasting domestic 
regulatory responses in each country has led to vastly different patterns in viral spread.  
The rate of infections in Korea began to decline within about six weeks’ time, while 
infections skyrocketed in the United States over that same period.4 Regulatory officials in 
South Korea immediately recognized the need for expansive testing to isolate the virus 
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and quickly brought together private companies to develop and administer coronavirus 
tests throughout the nation.5 That testing allowed government authorities to isolate 
infected and exposed individuals, effectively containing the virus’s early spread.  
By contrast, officials of the U.S. Centers for Disease Control and Prevention (CDC) 
and the Food and Drug Administration (FDA) spent weeks following a business-as-usual 
plan that wasted crucial time and allowed the virus to take root in major cities across the 
country.6 By the time the FDA finally exercised its authority to waive regulations that 
apply to testing in less dire circumstances, a containment strategy was too late. The spread 
of the virus across the United States has not only resulted in massive levels of premature 
mortality and other profound public health and economic effects within U.S. borders, but 
it also has complicated the overall battle against the global pandemic and contributed to 
an economic downturn around the world.  
The contrasting paths taken early by South Korea and the United States—a contrast 
sustained even more than a year later—make evident how much global health outcomes 
can vitally depend on high-quality domestic regulatory responses. And yet, despite the 
clear connection between global health and domestic regulatory governance, the 
scholarship and practice of domestic regulation has remained too disconnected from the 
scholarship and practice of global health governance. This disconnect exists 
notwithstanding important similarities between governance at both the global and 
domestic levels—and notwithstanding the lessons that practitioners and scholars of both 
regulation and global governance can learn from one another.  
Fortunately for regulatory scholars, the publication of Jennifer Prah Ruger’s recent 
book, Global Health Justice and Governance,7 provides an excellent basis for 
understanding the challenges of both global and domestic public health governance, and 
it offers an illuminating normative framework for the pursuit of global health justice. 
Global health governance and domestic regulatory governance share a common set of 
problems and common strategies for solving those problems. The common problems—
chiefly, externalities, coordination challenges, and distributional inequities—often exist 
on different planes, with regulatory problems primarily existing within the confines of 
individual jurisdictions, whereas global health problems inherently transcend national 
boundaries. But the different planes intersect with each other, as the current COVID-19 
pandemic makes plain.8 Moreover, some of the same underlying issues and challenges—
as well as an overall need for solutions of hard and soft power—cut across both policy 
planes and both fields of research. 
       By drawing out these connections, I seek in this essay to show what the vision of 
global health governance offered in Prah Ruger’s remarkable book has to offer 
scholars and practitioners of domestic regulatory governance. Prah Ruger argues 
that meaningful progress in securing global health justice ultimately depends on 
widely accepted norms and on the coordinated efforts of a diverse array of actors and 
institutions—or on what she calls “shared” health governance. I suggest that much the 
same is needed for domestic regulatory governance to be successful. Rather than seeing 
regulation as just a set of rules on the books, it is more useful to view domestic 
regulatory governance as a social enterprise involving the interaction of a diverse 
range of individuals and organizations. I conclude with seven lessons that domestic 
regulators can learn from Prah Ruger’s model of shared health governance.   
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COMMON PROBLEMS 
Prah Ruger begins her book presciently with accounts of previous deadly viral 
outbreaks: the 2013 Ebola epidemic that spread largely in Africa, and the 2003 SARS 
outbreak in Asia.9 The international spread of contagious pathogens presents a 
paradigmatic example of a global health problem. Prah Ruger acknowledges that 
contagion is also exactly the same kind of problem that is typically used to justify domestic 
regulation: a negative externality. Of course, when used to justify domestic regulation, 
externalities are treated as failures of the private market, because the terms of individual, 
private transactions do not fully account for the social costs of their spillovers.10 This is 
classically the case with pollution, and it provides the underlying justification for 
environmental regulation.  
With respect to global pandemics, the underlying failure is only partly one of the 
private marketplace. Private markets are no match for a viral spread, as the prevention, 
management, and elimination of that spread essentially constitutes a public good. The 
full costs of addressing contagion vastly exceed the individual benefits to any single actor, 
but if positive global health outcomes are achieved, their enjoyment cannot be denied to 
those who fail to contribute to them.11 Moreover, some of the measures needed to respond 
to pandemics—for example, quarantines—depend on the exercise of the kind of force 
which only domestic governments possess.12 This is why, as Prah Ruger points out, 
transnational pathogenic outbreaks are governance problems. A global pandemic 
represents the failure of national governments and international organizations to 
coordinate and function effectively to keep a viral outbreak contained. As she puts it, 
“[t]he international spread of pathogenic health risks reflects global health governance 
failures to respond effectively and to prevent local health harms from becoming 
worldwide risks.”13  
But externalities are not the only kind of global health problems that need 
attention—nor the only kind with direct parallels within the domain of regulation. Prah 
Ruger highlights another global health problem: the need for cross-border coordination—
or what regulatory scholars sometimes call regulatory cooperation or harmonization. 
Such cross-border problems arise, for example, when health care institutions are 
integrated across nations, as in Europe. Such integration demands basically either a 
common set of institutional standards and rules about costs and capacities, or a system 
of mutual recognition of different countries’ standards.14 In addition to the need to 
coordinate on health care delivery, a host of other problems also call for interjurisdictional 
cooperation, such as “counterfeit drugs,” “organ allocation and transplantation,” “overuse 
of antibiotics,” “medical tourism,” and “health worker migration.”15 When such cross-
border regulatory problems hold implications for global health, solving them necessitates 
both domestic regulatory responses and transnational regulatory coordination. This 
challenge is little different than other cross-border regulatory problems, such as those 
related to terrorism and money-laundering, refugees and immigration, and the safety of 
food, consumer, and pharmaceutical products in international trade.16  
A similar type of coordination problem arises inside nations themselves. This is 
especially the case in countries with federal systems of government. In the United States, 
for example, much attention has been paid to the coordination of medical licensing 
schemes so that health professionals initially licensed in one state can take advantage of 
changes in demographics or labor market conditions and relocate to other states.17 The 
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need for professional licensing coordination in the United States came into starker relief 
in response to the COVID-19 crisis. To prepare for a spike in patients and the prospect of 
health care workers getting sick at a time when hospitals were overwhelmed, New York 
City took steps in 2020 to welcome nurses and doctors from other states to fill its 
hospitals’ staffing needs.18 
 A third and final type of global health problem figures prominently throughout 
Prah Ruger’s book: inequality. This problem, too, has clear parallels within the domain of 
regulation.  
Prah Ruger assembles empirical findings from her own research and that of others 
which demonstrate troubling disparities that persist in health and access to health care, 
both across and within countries. For example, Prah Ruger observes that: 
 
While there has been much progress toward improving global health 
outcomes over the past several decades, global inequalities in adult and 
child mortality remain extreme; the gap is far from being closed, and the 
distribution of health burdens and benefits is drastically unequal. Mortality 
gaps between the richest and poorest countries are wide. Worldwide 99 
percent of maternal deals occur in developing countries.19 
 
Even within developed countries such as the United States, differences in health outcomes 
and standards of living can be extreme. Life expectancy, Prah Ruger reports, is twenty 
years greater on average in urban areas of Colorado than in North and South Dakota.20 
Residents in downtown Chicago live an average of sixteen years longer than their 
principally Black and Hispanic neighbors in the city’s south side.21  
 Despite the existence of such health disparities within a single country’s borders, 
it may be at first glance unclear the extent to which this inequality is fully a regulatory 
problem. Regulation has not been typically viewed as the principal domestic policy tool 
used to respond to societal inequality; taxation and social services tend to handle most of 
the distributional work from the standpoint of domestic policy.22 But laws and rules do 
make up an essential part of the policy toolkit that makes any tax or spending program 
work. Moreover, concerns about inequality do directly undergird many areas of 
regulation. Employment discrimination regulation and other civil rights laws expressly 
aim at social inequities produced by racial and gender biases.23 Environmental regulators 
are aware that pollution patterns contribute to disparate health outcomes along racial and 
socioeconomic lines, and, as a result, these regulators have sometimes developed 
programs or set enforcement priorities in an attempt to address environmental 
injustices.24 In these and other ways, the problem of inequality remains a matter of great 




Despite sharing a common set of problems with global health governance 
(externalities, cross-border coordination, and distributional inequities), regulatory 
governance might seem otherwise unrelated to global health governance. After all, 
regulation is associated with governmental entities that issue rules and rely on hard 
sanctions to enforce them—a model of power more compatible with the state-dominated 
world of what Prah Ruger calls international health governance. Prah Ruger makes clear 
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that international health governance, sometimes labeled “Westphalian” after the 1648 
Peace of Westphalia treaties, centered around nation-states and their sovereignty.25 That 
model of governance might have applied in the past, but it contrasts with what has become 
a system of global health governance since around the middle of the Twentieth Century.26  
This newer system of global health governance still accommodates the older 
Westphalian system—indeed, Prah Ruger acknowledges the continued “primacy of 
states”27 even today—but global health governance is not exclusively dominated by state 
actors. Instead, it reflects the reality that a multiplicity of non-state actors also shapes 
health outcomes and patterns around the world. Prah Ruger observes that the behaviors 
of these various actors are “uncoordinated,”28 “diffuse[, and] non-hierarchical.”29 They 
“lack any clear structure” because global health governance “does not clearly delineate 
roles for states, UN organizations, international organizations, civil society organizations, 
and public-private partnerships.”30 The chaotic state of affairs makes global governance 
something closer to a Hobbesian state of nature: “Fierce competition among actors and 
priorities results in end runs around national governments and the UN system.”31 As a 
result, it is more accurate to describe global health governance as “increasingly political 
and decreasingly technical and scientific.”32 
 Perhaps surprisingly, much the same can be said of domestic regulatory 
governance. Over the last several decades, both the practice and the study of regulation 
has shifted toward recognition of its more highly fragmented and contested state of 
affairs, replete with multiple public and private actors. No longer is regulation viewed as 
merely a formalistic application of binding rules imposed by government on private 
industry. Today, governments around the world deploy a mix of tools, and binding rules 
are only one of many.33 The work of regulators encompasses extensive use of public 
outreach efforts, information campaigns, guidance statements, and technical assistance. 
Voluntary recognition or rewards programs are now quite common,34 and public 
regulators take great interest in developing public-private partnerships in an effort to 
achieve regulatory goals.35  
Government regulators’ blending of binding legal rules with a variety of non-
binding strategies is possible due to the diverse nongovernmental actors that make up the 
social environment within which domestic regulatory governance operates. 
Nongovernmental forms of regulatory governance include self-regulatory schemes, such 
as the chemical industry’s Responsible Care program36 and the nuclear power industry’s 
Institute of Nuclear Power Operations.37 An extensive array of nongovernmental 
standards today are produced by industry groups and national and international 
standard-setting bodies, such as Underwriter’s Laboratories, the ASTM International, 
and the International Organization of Standardization.38 Regulators rely on these 
nongovernmental standards either to substitute for or complement binding governmental 
rules. And, not infrequently, these nongovernmental standards become adopted as 
binding governmental rules through a process known as incorporation by reference.39 
 Just as global health governance is more than just a Westphalian world of nation-
states, so too is regulatory governance about much more than a narrow realm of rules. 
Regulators, after all, are seeking to shape individual and organizational behavior in ways 
that solve problems or improve social or economic conditions. Both regulators and 
regulatory scholars thus understand that formal regulatory law is only one factor affecting 
relevant behavior. Other forces also can be used to achieve regulatory goals.40 Indeed, a 
widely accepted framework views the behavior of regulated businesses as shaped by 
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“three ‘licenses’”—a regulatory license (the formal law and its enforcement), an economic 
license (business imperatives), and a social license (community pressures and social 
norms).41 Both regulators and the businesses they oversee recognize the power of the so-
called social license in shaping firms’ behavior. The social license can be more demanding 
than either of the other licenses—even to the point that, within certain sectors and with 
respect to certain regulations, businesses will go beyond merely complying with their 
regulatory licenses and invest in costly measures that demonstrate their commitment to 
various environmental and social values, or what is sometimes referred to as corporate 
social responsibility.42  
In the end, domestic regulatory governance has much more in common with global 
health governance than it might first seem, even though these commonalities operate at 
different scales and within a different geographic scope. The types of problems that 
motivate global health governance also motivate regulatory governance. And just as 
global health governance comprises a broad, even eclectic, “set of standards, institutions, 
rules, norms, and regulations,”43 so too does regulatory governance comprise a pluralistic 
and intersecting set of internal and external behavioral drivers, as well as governmental 
and nongovernmental standards. As Prah Ruger shows, “[b]oth state and non-state actors 
are important instruments in achieving global health justice,”44 and so too are both state 
and non-state actors pivotal to the efficacy of regulatory governance in delivering public 




 As a result of these similarities in both problems and solutions, it should come as 
little surprise that many of the challenges that “vex” global health governance also often 
vex regulatory governance.  Prah Ruger describes an array of challenges at the global level: 
“hyperpluralism and fragmentation”; “incoherence, disorder, and inefficiency”; “blurred 
lines of responsibility”; “actors with divergent interests”; controversial “normative 
principles and processes”; policy uncertainties and shortage of data and “analysis of … 
problems”; power imbalances that lead some actors to exert “excessive political influence” 
of self-interested actors; and a lack of “credible compliance and dispute resolution 
mechanisms.”45   
This list describes astonishingly well the challenges that confront domestic 
regulators in advanced pluralist societies. Regulators in the United States and Europe, for 
example, find themselves increasingly operating in an environment of growing inequality, 
polarization, and adversarialism.46 The U.S. governing system in particular is said to lack 
“socially desirable incentives; rational selection of ends and means; accurate, unbiased, 
up-to-date information; the capacity to adapt promptly and flexibly to a changing policy 
environment; credibility to those actors whose expectations and responses will ultimately 
determine policy success or failure; and a bureaucracy that can manage and implement 
policies effectively in the real world.”47 The rise of the internet and social media has made 
sleepy backwaters of regulatory policy-making much more contentious, and the 
emergence of populism and still uglier forms of nationalism only add to today’s 
challenges.48 One need only look to ethnic conflicts, civil strife, and social movements as 
varied as Brexit, the Tea Party, Yellow Vests, and the Arab Spring to see the disruptive 
politics confronting domestic governance.   
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 When Prah Ruger observes that shared health governance—her aspirational but 
also positive or descriptive account of global health governance—depends largely on 
voluntary acceptance of norms, she could be writing about domestic regulatory 
governance as well. As she puts it, governance at the global level depends on an 
“overarching principle [of] voluntary compliance rising from common values, shared 
norms, and both substantive and procedural legitimacy.”49 Shared health governance, she 
writes, “relies on persuasion, education, and social movements to shape positive moral 
norms.”50 This is not qualitatively distinct from domestic regulatory governance. 
Admittedly, domestic regulation does afford the possibility of inducing behavioral 
compliance by way of punitive sanctions that transnational institutions cannot mete out 
to enforce international norms. Even though the importance of such enforcement power 
should not be discounted, regulators also aspire to solve problems rather than just impose 
penalties for their own sake.51 It marks success if regulators reach a point where threats 
and sanctions are no longer needed.  
At the domestic level, much regulatory compliance is effectively voluntary. This 
fact probably cannot be overstated. Domestic regulators rarely have oversight officers 
physically present at regulated industrial operations to observe them on a continuous 
basis. The number of inspectors needed to visit each regulated entity in any country’s 
economy, even just on annual basis, would likely well exceed available public resources. 
As a result, most regulated businesses, most of the time, escape any direct oversight of 
their compliance with regulation. And yet, compliance still occurs. Regulatory authorities 
depend on widely shared norms about the legitimacy of the law to induce compliance.52 
As Peter Schuck has written, “the mass compliance necessary for effective policy 
implementation depends far less upon episodic agency enforcement than upon a fragile 
condition: citizens’ internal sense of the rectitude, competence, and legitimacy of the law 
and of the officials who administer it.”53  
In the end, the differences between global governance challenges and domestic 
governance challenges are much less profound than they might first seem—at least as 
would seem apparent from the much too separated worlds that global governance 
scholars and regulatory governance scholars tend to inhabit. These differences between 
levels of governance are more a matter of degree than of kind. They are differences also 
in the units of analysis emphasized: individuals and firms for regulatory governance; 
nation-states and international actors for global governance. But they are not so different 
in terms of their basic underlying problems, solutions, and challenges.  
At any level, governance is about securing order, changing behavior, and managing 
disputes—all in an ever-changing world of competing interests and ideas. As such, 
governance is never easy, nor has it yet proven entirely satisfactory on any level.54  Still, 
once a greater number of scholars and policy actors recognize the commonalities between 
the realms of global and domestic governance, it should then become easier to learn 
lessons from each realm. 
 
LESSONS FOR REGULATORY GOVERNANCE 
 
A number of leading regulatory scholars—John Braithwaite, Susan Rose-
Ackerman, Charles Sabel, and Richard Stewart, to name a few—already have recognized 
commonalities between the domestic and global realms of governance and made 
important contributions to understanding governance of both kinds. But too many other 
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regulatory scholars tend toward a more limited focus solely on governance at the domestic 
level, passing up opportunities to learn from research on global governance. In addition 
to the much-too-separate realms inhabited by scholars, regulatory decision-makers could 
also learn much from those who study global governance. For anyone who tills mainly in 
domestic regulatory fields, Prah Ruger’s Global Health Justice and Governance inspires 
valuable lessons about the priorities and principles of high-quality domestic regulation.  
At least seven lessons for national and subnational regulators can be gleaned from 
Prah Ruger’s account of global health governance and especially from her case for a 
“shared” governance system grounded ultimately in a commonly accepted set of values 
and norms which intrinsically motivate the action needed to deliver global health 
justice.55 Given the necessary interdependence that Prah Ruger rightly recognizes exists 
between global health governance and domestic regulatory governance, domestic 
regulators have much they can learn from her illumination of the governance challenges 
associated with the quest for global health justice. Greater consideration of the following 
lessons could help promote not only improved health conditions at the national level, but 
also an improved health justice at the global level.56 
 
1. Pay attention to the distribution of regulatory outcomes and not merely their 
aggregate levels. 
 
Prah Ruger argues throughout her book for improvements in global health justice 
in distributional terms. She is rightly troubled by today’s gross disparities in both health 
outcomes and available health care resources. Using the level of health needed to sustain 
human flourishing as a benchmark, she emphasizes how people in different parts of the 
world lack even this basic floor.57 Public health officials around the world thus need to 
reduce shortfalls or gaps between that optimal floor and present-day reality.58 As she 
explains, “the health goals of a just society are to ensure all individuals have the ability to 
be healthy.”59 This approach does not demand that everyone in fact achieve identical 
levels of health. Nor does it deny the importance of efficiency and other aggregate 
measures of human welfare and development. After all, economic development provides 
an important pathway toward health justice. But justice does necessitate global 
movement toward minimizing what Prah Ruger terms “shortfall inequality”—that gap 
between needs and reality.60 It means reducing the number of people who lack basic 
health resources and acceptably safe conditions in which to work and live. 
Domestic regulators and regulatory scholars have an obvious role to play making 
progress toward health justice. Building codes, environmental regulations, and workplace 
health and safety standards all purport to deliver benefits that promote healthy conditions 
for the overall public, including those with the least resources. Yet regulators too seldom 
see themselves as in the business of promoting equality—whether of health or of any other 
regulatory goal. The principal metric for both regulatory design and evaluation has long 
tended to focus on aggregate effects—whether benefits overall justify costs overall.61 
Under the Kaldor-Hicks efficiency framework, as long as benefits exceed costs, a 
regulatory policy will be deemed successful. Seldom do regulators concern themselves 
with explicitly assessing how regulations’ benefits and costs are distributed across 
different segments of society. Even when regulatory agencies are supposed to consider 
the “distributive impacts” of their regulations,62 in practice they rarely conduct any 
systematic analysis of the distribution of regulatory costs and benefits.63 
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This lack of attention may stem, at least in part, from some uncertainty about 
exactly how to factor the distribution of impacts into any specific regulatory decision. How 
much regressivity in the distribution of regulatory impacts ought to be tolerated? Does 
the tolerable level depend on the size of the overall net benefits of the regulation? Perhaps 
if a new regulation results in benefits vastly outweighing its costs, then it should not 
matter if those with greater income or wealth in society are shown to benefit to a 
somewhat greater degree. To date, though, no common professional agreement has yet to 
be reached over what might constitute a tolerable level of regressivity in regulatory 
impacts nor over how tradeoffs between overall welfare and equity should be made.64 
Certainly nothing like the clear benchmark offered by the Kaldor-Hicks framework for 
efficiency exists for assessing the distribution of regulatory impacts. 
Even if such a benchmark did exist, there would still be a question of whether 
regulation is the appropriate policy arena within which to pursue distributional justice. 
Perhaps if a market failure exists and regulation fixes it, then that should be the end of 
the analysis and any resulting inequities created by the regulation would be better 
addressed through other programs and policies specifically aimed at redistribution.65 But 
even if that is so, the need for distributional analyses of regulatory impacts would still 
remain important. For one thing, even if regulators should mainly focus on aggregate net 
benefits, the possibility that a particular regulation or regulatory program might on 
occasion result in highly skewed regulatory impacts that severely harm already 
disadvantaged individuals in society should at least lead regulators to adjust their policy 
actions in those instances to reduce those harms. Furthermore, the mere step of 
identifying the distribution of regulatory effects could influence support for other social 
policies to offset the inequities. If regulators do little to estimate and disclose publicly the 
distribution of impacts, then tax or spending policies to offset regulations’ distributional 
inequities may be less likely ever to be pursued.66 It would be valuable for domestic 
regulators to heed the message in Prah Ruger’s book by doing more to emphasize equality 
concerns in regulatory governance. 
 
2. Use hard law strategically to reinforce soft law. 
 
Prah Ruger’s vision for “shared health governance” driven by widely accepted 
norms seems the apotheosis of soft power.67 Still, Prah Ruger recognizes that the full 
attainment of shared health governance cannot magically arise on its own accord. It 
depends on an iterated set of interactions between global health institutions and nation-
states. In this regard, she acknowledges that “sanctions, incentives, and punishments can 
be helpful.”68 Global actors can provide incentives for state action, and states in turn can 
then build up their own capacities to deliver on the promise health justice. Ideally, in the 
end, such iteration and progression lead to an equilibrium in which global and national 
actors follow shared norms to carry out responsibilities in ways that rely on their 
respective comparative advantages.69  
This model of shared health governance for the achievement of global health 
justice mirrors an excellent strategy for domestic regulation. Regulators will rarely, if 
ever, possess the resources needed to oversee all the actions of all the individuals and 
entities whose behavior regulation seeks to affect. As a result, regulatory organizations 
need to deploy their scarce resources strategically, trying to maximize public value from 
the steps that they are able to take.70 That means recognizing that punitive action is 
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costly—both in what it takes to document and enforce violations, but also in the potential 
for making regulation seem unreasonable and sparking resistance by regulated actors.71 
Regulators must use their limited enforcement resources wisely, such as by targeting 
actors that pose the greatest risks to society.  
When they approach regulatory encounters in a responsive fashion—that is, by first 
seeking to treat legal violations as problems to solve, and only later escalating punitively 
in response to regulated entities’ recalcitrance and resistance—regulators often seek to 
reinforce social norms, even if they do not necessarily substitute completely for them.72 
They frequently see their role not as a lone sheriff in town, but rather as an integral part 
of a larger social system shaping private behavior.73 Especially in the face of limited 
capacities for monitoring and oversight, they need to use their resources to complement, 
reinforce, and leverage private motivations and non-legal norms that can support socially 
optimal behavior.74   
 
3. Preserve and strengthen institutional trust and legitimacy. 
 
Social norms also affect the levels of public support, trust, and legitimacy that 
surround both domestic and international governing institutions. Prah Ruger 
acknowledges a set of process-oriented norms, such as those calling for institutions to 
exhibit neutral decision-making, transparency, and public participation.75 She also 
importantly recognizes a relationship between legitimacy and the substantive 
performance of any governing institution. This relationship manifests itself in two ways.76 
First, an institution’s substantive performance improves the degree of trust and 
legitimacy it earns from the public. Institutions that fail to deliver on the promise of 
improved health outcomes and equity will hardly engender much confidence, while those 
that deliver consistently high levels of substantive success will gain greater trust. Second, 
by adhering to fair, open, and accountable procedures, institutions build and maintain 
trust and legitimacy that in turn strengthens their ability to achieve substantive success. 
As Prah Ruger explains, global health governance “needs impartial institutions that 
engender trust and legitimacy” because “[o]nly this kind of institution can inspire 
acceptance and adherence.”77 
This is also true for domestic regulators. At the same time that these national and 
subnational institutions exist to deliver substantive regulatory outcomes, their leaders 
also will do well to attend to “perceptual outcomes,” such as public confidence, trust, and 
legitimacy.78 These perceptual outcomes amount to resources that are perhaps even more 
valuable than fiscal resources in terms of a regulatory body’s ability to achieve its mission. 
Trust and legitimacy can affect the level of voluntary compliance with regulations. They 
also help make it more likely that the regulatory body will receive the political support 
and budgetary outlays essential for substantive success.  
Perhaps nowhere has the importance of perceptual resources been better 
documented than with Dan Carpenter’s detailed history of the U.S. FDA.79 Carpenter 
demonstrates how the agency benefited for many decades from its ability to inculcate a 
reputation for scientific rigor and regulatory integrity. Of course, in more recent years, 
the FDA has struggled at times to live up to the stellar regulatory reputation it once held, 
encountering criticism over delays in its drug approval process and controversies over 
perceived regulatory oversteps, such as with respect to its assertion of authority to 
regulate tobacco in the 1990s. Most recently, the agency’s perceived initial slowness to 
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respond to the CoV-2 outbreak has put a critical spotlight on the FDA, and it continues to 
struggle to find an appropriate balance with respect to regulatory oversight of coronavirus 
testing, treatment, and vaccines.  
In fairness, of course, the current pandemic puts an enormous strain on nearly 
every institution. But the pandemic also demonstrates how vital it is, in times of crisis, for 
pivotal domestic regulators to be able to draw upon a reservoir of legitimacy and trust. In 
the end, the path toward the restoration of the economy following the Great Pandemic of 
2020 will likely depend on whether members of the public have confidence that their 
governmental institutions will adequately ensure their health and safety if they return to 
normal life.80 Pandemics make crystal clear what is also true in normal times: effective 
governance depends on trust—and the best regulators always seek to earn that trust, both 
through how they act and by what they achieve.81 
 
4. Be vigilant and dynamic in the face of changing behavior and conditions. 
 
 The world is constantly changing, with many moving parts interacting in different 
ways over time. As a result, to be effective, governance must remain a continuously active 
undertaking. Prah Ruger wisely warns against “indecisiveness”82 and a “fail[ure] to act.”83 
She urges a shared health governance that “is dynamic, addressing current and future 
challenges.”84  
In addition, Prah Ruger illustrates the dire consequences that can arise from 
inaction by recounting the 2007 fiasco involving Atlanta lawyer Andrew Speaker, who 
tested positive for a highly resistant strain of tuberculosis. Due to feeble efforts by public 
health officials in the state of Georgia, Speaker managed to take multiple international 
flights after having been diagnosed with tuberculosis and warned not to travel. Prah 
Ruger places much of the fault for the resulting public health dangers on the shoulders of 
the state of Georgia (ironically, where the U.S. CDC is headquartered) due to the state’s 
failure to provide “adequate surveillance, reporting, intervention, and personnel 
training.”85  
Prah Ruger’s example shows what can happen when domestic regulators succumb 
to “dithering” in the face of new risks or changing circumstances.86 More generally, the 
example provides a still broader lesson for regulators of all kinds never to treat the world 
as static. Economic and social conditions are constantly in flux; new technologies and new 
risks are regularly emerging. Regulation will not succeed if it is viewed a matter of just 
putting rules on the books. It must be agile and responsive. 
Effective regulation requires active “obligation management”—adding new 
requirements, modifying or lifting existing ones, monitoring conditions and overseeing 
compliance, and variously cajoling and threatening as needed.87 Regulatory effectiveness 
requires staying vigilant as to how regulated entities adapt in response to regulatory 
requirements. Even after a regulation is adopted, regulated entities are still likely to have 
interests at odds with the purposes of the regulation and therefore they will still have  self-
interested reasons to try to defeat or circumvent those purposes.88 “Agility” and 
“adaptability” may not be the kinds of adjectives that most people immediately associate 
with regulation, but many regulatory problems could be avoided with greater 
responsiveness by the leaders of regulatory organizations in the face of new problems or 
changes in industry behavior.89 
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5. Coordinate with other actors and institutions. 
 
At the global level, cooperation and coordination is essential. As Prah Ruger notes, 
“[m]ost observers agree that improving global health in the twenty-first century will 
require coordination and cooperation among states, using both legal and non-legal 
mechanisms.”90 Global health justice also requires coordination with various 
international institutions and non-state actors. It makes sense that Prah Ruger labels her 
aspirational model as one of shared health governance: 
 
No one (or set of) institution(s) or actor(s) on its own is able to perform [the] 
core functions and meet [the] fundamental needs [of global health justice]. 
As such, [shared health governance] parcels out respective roles and 
responsibilities at the global, state, local, and individual levels based on 
functional requirements and needs, identifying actors and institutions, their 
obligations, and how they are held accountable. 
 
In short, global health governance is a team sport. One might even say that it takes a 
village to govern the global village. 
The same applies with domestic regulatory governance. No regulatory 
organization on its own can gather all needed information, observe all possible regulated 
conduct, or change everyone’s behavior.91 To activate the behavioral change needed to 
solve problems, domestic regulatory bodies often work best if they fulfill a role akin to the 
conductor of an orchestra—that is, by directing and steering others and leveraging 
businesses’ own capacities to fulfill regulatory functions.92  
 In the end, “[a] regulator’s performance depends on other institutions and entities 
in the overarching nexus of relationships within which it is embedded.”93 The initial 
creation of a regulatory organization necessarily depends on others—e.g., members of a 
legislature—who give the regulatory body its authority, define its mandate and its legal 
constraints, and determine its funding and staffing levels. The regulatory organization is 
also embedded in a larger governmental system comprising other administrative agencies 
and bodies at different levels of government that interact with and affect the regulatory 
organization’s ability to carry out its mandate. The degree of public trust and legitimacy 
that the regulator enjoys will also be partly affected by the overall political environment 
within which it is situated. Because “[t]he regulator is just part of an overall ‘system’ that 
includes both other governmental entities as well as the industry that it regulates,” it must 
learn to act strategically and in coordination with these various other moving parts of the 
governance system.94 
 
6. Draw on a rigorous base of evidence and analysis. 
 
A domestic regulator, as with any institution involved in global health governance, 
can only expect to make sound decisions when its leaders are informed by the best 
available evidence and by carefully considered analysis. This is an obvious but too often 
neglected lesson that bears repeating.  
This lesson follows directly from Prah Ruger’s emphasis on the significant role for 
“empirical evidence of effectiveness, efficiency, and accountability” in global health 
governance.95 She favors reliance on “evidence-based standards and best practices” for 
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public health interventions,96 and warns appropriately that “[u]nintended consequences 
are always a danger.”97 She proposes a “Global Institute of Health and Medicine” that 
“would provide the needed scientific knowledge to craft effective policies and inform both 
domestic and global systems.”98 
 In much the same way, domestic regulatory decision-makers must seek out the 
best available scientific and economic analysis to inform policy and management 
decision-making. Yet the systematic development of regulatory analysis remains of 
relatively recent vintage and to date has been limited to mainly the prospective analysis 
of new regulations—so-called “RIA” or “regulatory impact assessment.”99 Although RIA 
practices can now be found in all the major economies, the same cannot be said of 
retrospective evaluation of regulations once adopted.100 Furthermore, numerous 
opportunities remain for regulators to strengthen their use of data analytics in 
enforcement and oversight management.101 
With the rise of populism around the world, certain countries are showing signs of 
devaluing expertise.102 At various points during the COVID-19 crisis, for example, the 
heads of state in the United States and Brazil openly flouted recommendations from 
scientists.103 U.S. President Donald Trump even endorsed the use of unproven and 
potentially dangerous medications, and he planted seeds of doubt about public health 
data on CoV-2 cases and fatalities.104 Not only do such actions undermine public trust and 
legitimacy, they may also encourage risky behavior that only exacerbates a public health 
crisis. Needless to say, domestic governance still can benefit from greater reliance on 
empirical evidence and analysis. 
 
7. Treat regulation as a relational activity rather than a mechanistic structure. 
 
As vital as it is for regulatory decisions to be informed by evidence and analysis, it 
is also important not to mistake regulation for little more than a challenging mathematical 
or engineering problem that can be solved by finding the right answer. As many of the 
preceding lessons already suggest, domestic regulation—as with governance more 
generally—is a relational activity. It is, at its best, very much “shared” governance in the 
fullest sense of that term: interactive and iterative, and intersecting with many different 
actors and sectors. Partly that is because the world is changing, with new regulated 
entities and restructured existing ones appearing constantly. But mainly regulation is 
relational because it is ultimately about human behavior and how to shape, direct, and 
modify that behavior. To regulate well requires actions taken by people in regulatory 
organizations to influence actions taken by people in regulated organizations, in the face 
of incentives and constraints created by other people in still other organizations. 
Regulation, in other words, is sociological.   
Regulation’s sociological or relational character begins with its very origins. The 
process of initially authorizing regulation of a sector or an activity usually gives regulation 
the kind of public backing that Prah Ruger argues is needed to make progress toward 
global health justice.105 The public backing which leads legislatures to pass regulation-
authorizing legislation stems often from either broad social movements or from crises or 
catastrophes that make the need for regulation more evident to the broader public.106 
Regardless of new legislation’s precise path, the early years of any new regulatory regime 
tend to enjoy some political and social tailwinds behind it. Those tailwinds, and any new 
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social norms they engender, help reinforce the same behavioral changes that any new set 
of regulations will aim to foster.  
Regulation does not operate in a social vacuum. It is situated in a social and 
political context that affects its performance and meaning. This is so despite the fact that 
many regulators and scholars still seem to treat the most important regulatory questions 
as being ones of how the rulebook should be written. These drafting and design questions 
are certainly not unimportant, and I would not suggest for a moment that they should be 
answered based on hunches instead of sound analysis. But getting the rule’s design “right” 
is only part of the activity of regulating. The rules on the books are only part of the story.  
Regulation is not a machine, but instead is an ongoing, and often conflict-ridden, 
set of relationships between people in and out of government. Recognizing this reality 
both follows from and reinforces many of the preceding lessons—such as those about 
wielding hard power to reinforce soft power, remaining vigilant and dynamic, and 
coordinating with others. Most importantly, such recognition helps to explain why 
domestic regulatory governance and global health governance have so much in common: 




The relational and interactive nature of governance may be clearest on the global 
stage, where actors and institutions from many different cultures and legal systems must 
cooperate in a non-hierarchical social order. But that same relational, interactive 
character also describes governance at the domestic level. Global health governance and 
domestic regulatory governance share much in common, with some of the same general 
goals, strategies, and challenges. A realization of these commonalities should help 
facilitate greater cross-learning by scholars and practitioners who too often work within 
relatively limited domains. It is for this reason that an attentive reading of Jennifer Prah 
Ruger’s recent book, Global Health Justice and Governance, can repay students of 
domestic regulation, offering a set of important lessons about how to approach the task 
of regulating well.    
The Great Pandemic that emerged in 2020 has laid bare a number of harsh realities 
about inequities of health conditions and economic security around the world, revealing 
how much work remains to be done to deliver justice for all of humanity. The pandemic 
has also demonstrated the crucial role for high-quality domestic governance in 
successfully preventing and responding to global health problems.107 The pursuit of 
excellence in domestic regulation will thus be integral to efforts to secure improved health 
conditions throughout the world. In that pursuit, regulators, policymakers, and members 
of the public will do well to keep in mind that regulation is not a self-implementing 
machine that operates separate from society. Regulation does not run on autopilot. 
Instead, it demands ongoing vigilance, adaptability, and responsiveness to changing 
circumstances and new risks. It requires adequate leadership, expertise, and resources to 
engage on an ongoing basis with a host of governmental and nongovernmental actors—
not merely to deploy and enforce binding rules, but also to leverage social norms and 
other private pressures for behavioral change. Prah Ruger’s model of shared health 
governance at the global level offers its readers an important vision for how regulators 
can best help make the world a better and healthier place. 
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